ベンラファキシン (Japanese Wikipedia)

Analysis of information sources in references of the Wikipedia article "ベンラファキシン" in Japanese language version.

refsWebsite

Global rank Japanese rank

62nih.gov

4^th place

24^th place

40doi.org

2^nd place

6^th place

4springer.com

274^th place

596^th place

3psychiatryonline.org

4,032^nd place

6,830^th place

2secretariat.ne.jp

low place

4,824^th place

2web.archive.org

1^st place

2fda.gov

447^th place

1,043^rd place

2oxfordjournals.org

1,389^th place

1,710^th place

1tga.gov.au

3,984^th place

low place

1nature.com

234^th place

363^rd place

1pmda.go.jp

6,690^th place

394^th place

1drugs.com

399^th place

1,603^rd place

1mayoclinic.com

3,634^th place

low place

1stanford.edu

179^th place

608^th place

1medicalxpress.com

8,255^th place

low place

1wyeth.com

low place

1dailymail.co.uk

219^th place

241^st place

1jamanetwork.com

2,650^th place

3,384^th place

1bmj.com

1,226^th place

1,988^th place

1priory.com

low place

1clinchem.org

low place

1thelancet.com

2,393^rd place

4,709^th place

1njmonline.nl

low place

1clinicaltrials.gov

5,225^th place

low place

1cambridge.org

305^th place

825^th place

1snpedia.com

low place

bmj.com

Rubino A, Roskell N, Tennis P, Mines D, Weich S, Andrews E (2007). “Risk of suicide during treatment with venlafaxine, citalopram, fluoxetine, and dothiepin: retrospective cohort study” (PDF). British Medical Journal 334 (7587): 242. doi:10.1136/bmj.39041.445104.BE. PMC 1790752. PMID 17164297.

cambridge.org

stahlonline.cambridge.org

“Stahl's Essential Psychopharmacology – Cambridge University Press”. Stahlonline.cambridge.org. 2013年11月21日閲覧。

clinchem.org

Sena SF, Kazimi S, Wu AH (April 2002). “False-positive phencyclidine immunoassay results caused by venlafaxine and O-desmethylvenlafaxine” (PDF). Clinical Chemistry 48 (4): 676–7. PMID 11901076.

clinicaltrials.gov

“Acute Effectiveness of Additional Drugs to the Standard Treatment of Depression”. ClinicalTrials.gov (2008年). 2013年11月21日閲覧。

dailymail.co.uk

Nakhai-Pour HR, Broy P, Bérard A (2010). “Use of antidepressants during pregnancy and the risk of spontaneous abortion”. Canadian Medical Association Journal 182 (10): 1031–1037. doi:10.1503/cmaj.091208. PMC 2900326. PMID 20513781. 非専門家向けの内容要旨.

doi.org

Muth EA, Haskins JT, Moyer JA, Husbands GE, Nielsen ST, Sigg EB (December 1986). “Antidepressant biochemical profile of the novel bicyclic compound Wy-45,030, an ethyl cyclohexanol derivative”. Biochemical Pharmacology 35 (24): 4493–7. doi:10.1016/0006-2952(86)90769-0. PMID 3790168.
Yardley JP, Husbands GE, Stack G, Butch J, Bicksler J, Moyer JA, Muth EA, Andree T, Fletcher H, James MN (October 1990). “2-Phenyl-2-(1-hydroxycycloalkyl)ethylamine derivatives: synthesis and antidepressant activity”. Journal of Medicinal Chemistry 33 (10): 2899–905. doi:10.1021/jm00172a035. PMID 1976813.
Bymaster FP, Dreshfield-Ahmad LJ, Threlkeld PG, Shaw JL, Thompson L, Nelson DL, Hemrick-Luecke SK, Wong DT (December 2001). “Comparative affinity of duloxetine and venlafaxine for serotonin and norepinephrine transporters in vitro and in vivo, human serotonin receptor subtypes, and other neuronal receptors” (PDF). Neuropsychopharmacology 25 (6): 871–80. doi:10.1016/S0893-133X(01)00298-6. PMID 11750180.
White N, Litovitz T, Clancy C (December 2008). “Suicidal antidepressant overdoses: a comparative analysis by antidepressant type.”. Journal of Medical Toxicology 4 (4): 238–50. doi:10.1007/BF03161207. PMC 3550116. PMID 19031375.
Pae CU (December 2011). “Desvenlafaxine in the treatment of major depressive disorder.”. Expert Opinion on Pharmacotherapy 12 (18): 2923–8. doi:10.1517/14656566.2011.636033. PMID 22098230.
Parker G, Blennerhassett J; Blennerhassett (April 1998). “Withdrawal reactions associated with venlafaxine”. The Australian and New Zealand Journal of Psychiatry 32 (2): 291–4. doi:10.3109/00048679809062742. PMID 9588310.
Redrobe JP, Bourin M, Colombel MC, Baker GB (July 1998). “Dose-dependent noradrenergic and serotonergic properties of venlafaxine in animal models indicative of antidepressant activity”. Psychopharmacology 138 (1): 1–8. doi:10.1007/s002130050638. PMID 9694520.
Grothe DR, Scheckner B, Albano D (May 2004). “Treatment of pain syndromes with venlafaxine.”. Pharmacotherapy 24 (5): 621–9. doi:10.1592/phco.24.6.621.34748. PMID 15162896.
Schober CE, Ansani NT (2003). “Venlafaxine hydrochloride for the treatment of hot flashes”. The Annals of Pharmacotherapy 37 (11): 1703–7. doi:10.1345/aph.1C483. PMID 14565812.
Ghanizadeh A, Freeman RD, Berk M (March 2013). “Efficacy and adverse effects of venlafaxine in children and adolescents with ADHD: a systematic review of non-controlled and controlled trials”. Reviews on recent clinical trials 8 (1): 2–8. doi:10.2174/1574887111308010002. PMID 23157376.
Pae CU, Lim HK, Ajwani N, Lee C, Patkar AA (June 2007). “Extended-release formulation of venlafaxine in the treatment of post-traumatic stress disorder.”. Expert Review of Neurotherapeutics 7 (6): 603–15. doi:10.1586/14737175.7.6.603. PMID 17563244.
Golden RN, Nicholas L (2000). “Antidepressant efficacy of venlafaxine”. Depression and Anxiety 12 Suppl 1: 45–9. doi:10.1002/1520-6394(2000)12:1+<45::AID-DA5>3.0.CO;2-5. PMID 11098413.
Thase ME, Clayton AH, Haight BR, Thompson AH, Modell JG, Johnston JA (2006). “A double-blind comparison between bupropion XL and venlafaxine XR: sexual functioning, antidepressant efficacy, and tolerability”. Journal of Clinical Psychopharmacology 26 (5): 482–8. doi:10.1097/01.jcp.0000239790.83707.ab. PMID 16974189.
Lenox-Smith AJ, Jiang Q (2008). “Venlafaxine extended release versus citalopram in patients with depression unresponsive to a selective serotonin reuptake inhibitor”. International Clinical Psychopharmacology 23 (3): 113–9. doi:10.1097/YIC.0b013e3282f424c2. PMID 18408525.
Jin, Hua; Shih, Pei-an Betty; Golshan, Shahrokh; Mudaliar, Sunder; Henry, Robert; Glorioso, Danielle K.; Arndt, Stephan; Kraemer, Helena C. et al. (January 2013). “Comparison of Longer-Term Safety and Effectiveness of 4 Atypical Antipsychotics in Patients Over Age 40”. The Journal of Clinical Psychiatry 74 (01): 10–18. doi:10.4088/JCP.12m08001. PMID 23218100.
Broy P, Bérard A (2010). “Gestational exposure to antidepressants and the risk of spontaneous abortion: A review”. Current drug delivery 7 (1): 76–92. doi:10.2174/156720110790396508. PMID 19863482.
Nakhai-Pour HR, Broy P, Bérard A (2010). “Use of antidepressants during pregnancy and the risk of spontaneous abortion”. Canadian Medical Association Journal 182 (10): 1031–1037. doi:10.1503/cmaj.091208. PMC 2900326. PMID 20513781. 非専門家向けの内容要旨.
Gentile S (2005). “The safety of newer antidepressants in pregnancy and breastfeeding”. Drug Saf 28 (2): 137–52. doi:10.2165/00002018-200528020-00005. PMID 15691224.
Ferreira E, Carceller AM, Agogué C, Martin BZ, St-André M, Francoeur D, Bérard A (2007). “[Effects of selective serotonin reuptake inhibitors and venlafaxine during pregnancy in term and preterm neonates]”. Pediatrics 119 (1): 52–9. doi:10.1542/peds.2006-2133. PMID 17200271.
Moses-Kolko EL, Bogen D, Perel J, Bregar A, Uhl K, Levin B, Wisner KL (2005). “Neonatal signs after late in utero exposure to serotonin reuptake inhibitors: Literature review and implications for clinical applications”. The Journal of the American Medical Association 293 (19): 2372–83. doi:10.1001/jama.293.19.2372. PMID 15900008.
Gibbons RD, Brown CH, Hur K, Davis J, Mann JJ (June 2012). “Suicidal thoughts and behavior with antidepressant treatment: reanalysis of the randomized placebo-controlled studies of fluoxetine and venlafaxine”. Arch. Gen. Psychiatry 69 (6): 580–7. doi:10.1001/archgenpsychiatry.2011.2048. PMC 3367101. PMID 22309973.
Tiihonen J, Lönnqvist J, Wahlbeck K, Klaukka T, Tanskanen A, Haukka J (December 2006). “Antidepressants and the risk of suicide, attempted suicide, and overall mortality in a nationwide cohort” (PDF). Archives of General Psychiatry 63 (12): 1358–67. doi:10.1001/archpsyc.63.12.1358. PMID 17146010.
Rubino A, Roskell N, Tennis P, Mines D, Weich S, Andrews E (2007). “Risk of suicide during treatment with venlafaxine, citalopram, fluoxetine, and dothiepin: retrospective cohort study” (PDF). British Medical Journal 334 (7587): 242. doi:10.1136/bmj.39041.445104.BE. PMC 1790752. PMID 17164297.
Emslie GJ, Findling RL, Yeung PP, Kunz NR, Li Y (2007). “Venlafaxine ER for the treatment of pediatric subjects with depression: results of two placebo-controlled trials”. Journal of the American Academy of Child and Adolescent Psychiatry 46 (4): 479–88. doi:10.1097/chi.0b013e31802f5f03. PMID 17420682.
Brent DA, Emslie GJ, Clarke GN, Asarnow J, Spirito A, Ritz L, Vitiello B, Iyengar S, Birmaher B, Ryan ND, Zelazny J, Onorato M, Kennard B, Mayes TL, Debar LL, McCracken JT, Strober M, Suddath R, Leonard H, Porta G, Keller MB (April 2009). “Predictors of spontaneous and systematically assessed suicidal adverse events in the treatment of SSRI-resistant depression in adolescents (TORDIA) study” (PDF). The American Journal of Psychiatry 166 (4): 418–26. doi:10.1176/appi.ajp.2008.08070976. PMC 3593721. PMID 19223438.
Haddad PM (March 2001). “Antidepressant discontinuation syndromes” (PDF). Drug Safety 24 (3): 183–97. doi:10.2165/00002018-200124030-00003. PMID 11347722.
Dunkley EJ, Isbister GK, Sibbritt D, Dawson AH, Whyte IM (September 2003). “The Hunter Serotonin Toxicity Criteria: simple and accurate diagnostic decision rules for serotonin toxicity” (PDF). QJM: Monthly Journal of the Association of Physicians 96 (9): 635–42. doi:10.1093/qjmed/hcg109. PMID 12925718.
Kolecki P (July–August 1997). “Isolated venlafaxine-induced serotonin syndrome”. Journal of Emergency Medicine 15 (4): 491–3. doi:10.1016/S0736-4679(97)00078-4. PMID 9279702.
Pan JJ, Shen WW (February 2003). “Serotonin syndrome induced by low-dose venlafaxine”. The Annals of Pharmacotherapy 37 (2): 209–11. doi:10.1345/aph.1C021. PMID 12549949.
Thundiyil JG, Kearney TE, Olson KR (March 2007). “Evolving epidemiology of drug-induced seizures reported to a Poison Control Center System” (PDF). Journal of Medical Toxicology 3 (1): 15–9. doi:10.1007/BF03161033. PMC 3550124. PMID 18072153.
Pacchiarotti I, Bond DJ, Baldessarini RJ, Nolen WA, Grunze H, Licht RW, Post RM, Berk M, Goodwin GM, Sachs GS, Tondo L, Findling RL, Youngstrom EA, Tohen M, Undurraga J, González-Pinto A, Goldberg JF, Yildiz A, Altshuler LL, Calabrese JR, Mitchell PB, Thase ME, Koukopoulos A, Colom F, Frye MA, Malhi GS, Fountoulakis KN, Vázquez G, Perlis RH, Ketter TA, Cassidy F, Akiskal H, Azorin JM, Valentí M, Mazzei DH, Lafer B, Kato T, Mazzarini L, Martínez-Aran A, Parker G, Souery D, Ozerdem A, McElroy SL, Girardi P, Bauer M, Yatham LN, Zarate CA, Nierenberg AA, Birmaher B, Kanba S, El-Mallakh RS, Serretti A, Rihmer Z, Young AH, Kotzalidis GD, MacQueen GM, Bowden CL, Ghaemi SN, Lopez-Jaramillo C, Rybakowski J, Ha K, Perugi G, Kasper S, Amsterdam JD, Hirschfeld RM, Kapczinski F, Vieta E (November 2013). “The International Society for Bipolar Disorders (ISBD) task force report on antidepressant use in bipolar disorders”. The American Journal of Psychiatry 170 (1): 1249–62. doi:10.1176/appi.ajp.2013.13020185. PMID 24030475.
Santos PM, López-García P, Navarro JS, Fernández AS, Sádaba B, Vidal JP (February 2007). “False positive phencyclidine results caused by venlafaxine” (PDF). The American Journal of Psychiatry 164 (2): 349. doi:10.1176/appi.ajp.164.2.349. PMID 17267806.
Cipriani A, Furukawa TA, Salanti G, et al. (2009-02-28). “Comparative efficacy and acceptability of 12 new-generation antidepressants: a multiple-treatments meta-analysis.”. Lancet 373 (9665): 746-58. doi:10.1016/S0140-6736(09)60046-5. PMID 19185342.
Taylor D, Lenox-Smith A, Bradley A (June 2013). “A review of the suitability of duloxetine and venlafaxine for use in patients with depression in primary care with a focus on cardiovascular safety, suicide and mortality due to antidepressant overdose.”. Therapeutic Advances in Psychopharmacology 3 (3): 151–61. doi:10.1177/2045125312472890. PMC 3805457. PMID 24167687.
Goeringer KE, McIntyre IM, Drummer OH (2001). “Postmortem tissue concentrations of venlafaxine”. Forensic Science International 121 (1–2): 70–5. doi:10.1016/S0379-0738(01)00455-8. PMID 11516890.
Wellington K, Perry CM (2001). “Venlafaxine extended-release: a review of its use in the management of major depression” (PDF). CNS Drugs 15 (8): 643–69. doi:10.2165/00023210-200115080-00007. PMID 11524036.
Schreiber S, Bleich A, Pick CG (February–April 2002). “Venlafaxine and mirtazapine: different mechanisms of antidepressant action, common opioid-mediated antinociceptive effects—a possible opioid involvement in severe depression?”. Journal of Molecular Neuroscience, MN 18 (1–2): 143–9. doi:10.1385/JMN:18:1-2:143. PMID 11931344.
Shams ME, Arneth B, Hiemke C, Dragicevic A, Müller MJ, Kaiser R, Lackner K, Härtter S; Arneth; Hiemke; Dragicevic; Müller; Kaiser; Lackner; Härtter (October 2006). “CYP2D6 polymorphism and clinical effect of the antidepressant venlafaxine”. Journal of Clinical Pharmacy and Therapeutics 31 (5): 493–502. doi:10.1111/j.1365-2710.2006.00763.x. PMID 16958828.
Uhr M, Tontsch A, Namendorf C, Ripke S, Lucae S, Ising M, Dose T, Ebinger M, Rosenhagen M, Kohli M, Kloiber S, Salyakina D, Bettecken T, Specht M, Pütz B, Binder EB, Müller-Myhsok B, Holsboer F; Tontsch; Namendorf; Ripke; Lucae; Ising; Dose; Ebinger et al. (2008). “Polymorphisms in the drug transporter gene ABCB1 predict antidepressant treatment response in depression”. Neuron 57 (2): 203–209. doi:10.1016/j.neuron.2007.11.017. PMID 18215618.
Whyte IM, Dawson AH, Buckley NA; Dawson; Buckley (May 2003). “Relative toxicity of venlafaxine and selective serotonin reuptake inhibitors in overdose compared to tricyclic antidepressants” (PDF). QJM: Monthly Journal of the Association of Physicians 96 (5): 369–74. doi:10.1093/qjmed/hcg062. PMID 12702786.

drugs.com

“venlafaxine-hydrochloride”. The American Society of Health-System Pharmacists. 2011年4月3日閲覧。

fda.gov

“Overview for December 13 Meeting of Psychopharmacologic Drugs Advisory Committee” (PDF). Food and Drug Administration: Center for Drug Evaluation and Research (2006年11月16日). 2007年3月16日時点のオリジナルよりアーカイブ。2007年6月20日閲覧。
“Wyeth Letter to Health Care Providers”. Wyeth Pharmaceuticals Inc (2006年). 2009年8月6日閲覧。

jamanetwork.com

archpsyc.jamanetwork.com

Tiihonen J, Lönnqvist J, Wahlbeck K, Klaukka T, Tanskanen A, Haukka J (December 2006). “Antidepressants and the risk of suicide, attempted suicide, and overall mortality in a nationwide cohort” (PDF). Archives of General Psychiatry 63 (12): 1358–67. doi:10.1001/archpsyc.63.12.1358. PMID 17146010.

mayoclinic.com

Mayo Clinic staff (2005年). “Beyond hormone therapy: Other medicines may help”. Hot flashes: Ease the discomfort of menopause. Mayo Clinic. 2005年8月19日閲覧。

medicalxpress.com

“Two-drug combo helps older adults with hard-to-treat depression”. Medical Express (2015年9月27日). 2015年10月1日閲覧。

nature.com

Bymaster FP, Dreshfield-Ahmad LJ, Threlkeld PG, Shaw JL, Thompson L, Nelson DL, Hemrick-Luecke SK, Wong DT (December 2001). “Comparative affinity of duloxetine and venlafaxine for serotonin and norepinephrine transporters in vitro and in vivo, human serotonin receptor subtypes, and other neuronal receptors” (PDF). Neuropsychopharmacology 25 (6): 871–80. doi:10.1016/S0893-133X(01)00298-6. PMID 11750180.

nih.gov

pubmed.ncbi.nlm.nih.gov

Muth EA, Haskins JT, Moyer JA, Husbands GE, Nielsen ST, Sigg EB (December 1986). “Antidepressant biochemical profile of the novel bicyclic compound Wy-45,030, an ethyl cyclohexanol derivative”. Biochemical Pharmacology 35 (24): 4493–7. doi:10.1016/0006-2952(86)90769-0. PMID 3790168.
Yardley JP, Husbands GE, Stack G, Butch J, Bicksler J, Moyer JA, Muth EA, Andree T, Fletcher H, James MN (October 1990). “2-Phenyl-2-(1-hydroxycycloalkyl)ethylamine derivatives: synthesis and antidepressant activity”. Journal of Medicinal Chemistry 33 (10): 2899–905. doi:10.1021/jm00172a035. PMID 1976813.
Bymaster FP, Dreshfield-Ahmad LJ, Threlkeld PG, Shaw JL, Thompson L, Nelson DL, Hemrick-Luecke SK, Wong DT (December 2001). “Comparative affinity of duloxetine and venlafaxine for serotonin and norepinephrine transporters in vitro and in vivo, human serotonin receptor subtypes, and other neuronal receptors” (PDF). Neuropsychopharmacology 25 (6): 871–80. doi:10.1016/S0893-133X(01)00298-6. PMID 11750180.
White N, Litovitz T, Clancy C (December 2008). “Suicidal antidepressant overdoses: a comparative analysis by antidepressant type.”. Journal of Medical Toxicology 4 (4): 238–50. doi:10.1007/BF03161207. PMC 3550116. PMID 19031375.
Pae CU (December 2011). “Desvenlafaxine in the treatment of major depressive disorder.”. Expert Opinion on Pharmacotherapy 12 (18): 2923–8. doi:10.1517/14656566.2011.636033. PMID 22098230.
Parker G, Blennerhassett J; Blennerhassett (April 1998). “Withdrawal reactions associated with venlafaxine”. The Australian and New Zealand Journal of Psychiatry 32 (2): 291–4. doi:10.3109/00048679809062742. PMID 9588310.
Redrobe JP, Bourin M, Colombel MC, Baker GB (July 1998). “Dose-dependent noradrenergic and serotonergic properties of venlafaxine in animal models indicative of antidepressant activity”. Psychopharmacology 138 (1): 1–8. doi:10.1007/s002130050638. PMID 9694520.
Grothe DR, Scheckner B, Albano D (May 2004). “Treatment of pain syndromes with venlafaxine.”. Pharmacotherapy 24 (5): 621–9. doi:10.1592/phco.24.6.621.34748. PMID 15162896.
Schober CE, Ansani NT (2003). “Venlafaxine hydrochloride for the treatment of hot flashes”. The Annals of Pharmacotherapy 37 (11): 1703–7. doi:10.1345/aph.1C483. PMID 14565812.
Ghanizadeh A, Freeman RD, Berk M (March 2013). “Efficacy and adverse effects of venlafaxine in children and adolescents with ADHD: a systematic review of non-controlled and controlled trials”. Reviews on recent clinical trials 8 (1): 2–8. doi:10.2174/1574887111308010002. PMID 23157376.
Pae CU, Lim HK, Ajwani N, Lee C, Patkar AA (June 2007). “Extended-release formulation of venlafaxine in the treatment of post-traumatic stress disorder.”. Expert Review of Neurotherapeutics 7 (6): 603–15. doi:10.1586/14737175.7.6.603. PMID 17563244.
Golden RN, Nicholas L (2000). “Antidepressant efficacy of venlafaxine”. Depression and Anxiety 12 Suppl 1: 45–9. doi:10.1002/1520-6394(2000)12:1+<45::AID-DA5>3.0.CO;2-5. PMID 11098413.
Thase ME, Clayton AH, Haight BR, Thompson AH, Modell JG, Johnston JA (2006). “A double-blind comparison between bupropion XL and venlafaxine XR: sexual functioning, antidepressant efficacy, and tolerability”. Journal of Clinical Psychopharmacology 26 (5): 482–8. doi:10.1097/01.jcp.0000239790.83707.ab. PMID 16974189.
Lenox-Smith AJ, Jiang Q (2008). “Venlafaxine extended release versus citalopram in patients with depression unresponsive to a selective serotonin reuptake inhibitor”. International Clinical Psychopharmacology 23 (3): 113–9. doi:10.1097/YIC.0b013e3282f424c2. PMID 18408525.
Jin, Hua; Shih, Pei-an Betty; Golshan, Shahrokh; Mudaliar, Sunder; Henry, Robert; Glorioso, Danielle K.; Arndt, Stephan; Kraemer, Helena C. et al. (January 2013). “Comparison of Longer-Term Safety and Effectiveness of 4 Atypical Antipsychotics in Patients Over Age 40”. The Journal of Clinical Psychiatry 74 (01): 10–18. doi:10.4088/JCP.12m08001. PMID 23218100.
Courtney DB (2004). “Selective serotonin reuptake inhibitor and venlafaxine use in children and adolescents with major depressive disorder: a systematic review of published randomized controlled trials”. Canadian Journal of Psychiatry 49 (8): 557–63. PMID 15453105.
Broy P, Bérard A (2010). “Gestational exposure to antidepressants and the risk of spontaneous abortion: A review”. Current drug delivery 7 (1): 76–92. doi:10.2174/156720110790396508. PMID 19863482.
Nakhai-Pour HR, Broy P, Bérard A (2010). “Use of antidepressants during pregnancy and the risk of spontaneous abortion”. Canadian Medical Association Journal 182 (10): 1031–1037. doi:10.1503/cmaj.091208. PMC 2900326. PMID 20513781. 非専門家向けの内容要旨.
Gentile S (2005). “The safety of newer antidepressants in pregnancy and breastfeeding”. Drug Saf 28 (2): 137–52. doi:10.2165/00002018-200528020-00005. PMID 15691224.
de Moor RA, Mourad L, ter Haar J, Egberts AC (2003). “[Withdrawal symptoms in a neonate following exposure to venlafaxine during pregnancy]”. Ned Tijdschr Geneeskd 147 (28): 1370–2. PMID 12892015.
Ferreira E, Carceller AM, Agogué C, Martin BZ, St-André M, Francoeur D, Bérard A (2007). “[Effects of selective serotonin reuptake inhibitors and venlafaxine during pregnancy in term and preterm neonates]”. Pediatrics 119 (1): 52–9. doi:10.1542/peds.2006-2133. PMID 17200271.
Moses-Kolko EL, Bogen D, Perel J, Bregar A, Uhl K, Levin B, Wisner KL (2005). “Neonatal signs after late in utero exposure to serotonin reuptake inhibitors: Literature review and implications for clinical applications”. The Journal of the American Medical Association 293 (19): 2372–83. doi:10.1001/jama.293.19.2372. PMID 15900008.
Gibbons RD, Brown CH, Hur K, Davis J, Mann JJ (June 2012). “Suicidal thoughts and behavior with antidepressant treatment: reanalysis of the randomized placebo-controlled studies of fluoxetine and venlafaxine”. Arch. Gen. Psychiatry 69 (6): 580–7. doi:10.1001/archgenpsychiatry.2011.2048. PMC 3367101. PMID 22309973.
Tiihonen J, Lönnqvist J, Wahlbeck K, Klaukka T, Tanskanen A, Haukka J (December 2006). “Antidepressants and the risk of suicide, attempted suicide, and overall mortality in a nationwide cohort” (PDF). Archives of General Psychiatry 63 (12): 1358–67. doi:10.1001/archpsyc.63.12.1358. PMID 17146010.
Rubino A, Roskell N, Tennis P, Mines D, Weich S, Andrews E (2007). “Risk of suicide during treatment with venlafaxine, citalopram, fluoxetine, and dothiepin: retrospective cohort study” (PDF). British Medical Journal 334 (7587): 242. doi:10.1136/bmj.39041.445104.BE. PMC 1790752. PMID 17164297.
Emslie GJ, Findling RL, Yeung PP, Kunz NR, Li Y (2007). “Venlafaxine ER for the treatment of pediatric subjects with depression: results of two placebo-controlled trials”. Journal of the American Academy of Child and Adolescent Psychiatry 46 (4): 479–88. doi:10.1097/chi.0b013e31802f5f03. PMID 17420682.
Brent DA, Emslie GJ, Clarke GN, Asarnow J, Spirito A, Ritz L, Vitiello B, Iyengar S, Birmaher B, Ryan ND, Zelazny J, Onorato M, Kennard B, Mayes TL, Debar LL, McCracken JT, Strober M, Suddath R, Leonard H, Porta G, Keller MB (April 2009). “Predictors of spontaneous and systematically assessed suicidal adverse events in the treatment of SSRI-resistant depression in adolescents (TORDIA) study” (PDF). The American Journal of Psychiatry 166 (4): 418–26. doi:10.1176/appi.ajp.2008.08070976. PMC 3593721. PMID 19223438.
Haddad PM (March 2001). “Antidepressant discontinuation syndromes” (PDF). Drug Safety 24 (3): 183–97. doi:10.2165/00002018-200124030-00003. PMID 11347722.
Fava M, Mulroy R, Alpert J, Nierenberg AA, Rosenbaum JF (December 1997). “Emergence of adverse events following discontinuation of treatment with extended-release venlafaxine”. The American Journal of Psychiatry 154 (12): 1760–2. PMID 9396960.
Campagne DM (2005). “Venlafaxine and Serious Withdrawal Symptoms: Warning to Drivers”. Medscape General Medicine (Ncbi.nlm.nih.gov) 7 (3): 22. PMC 1681629. PMID 16369248.
Dunkley EJ, Isbister GK, Sibbritt D, Dawson AH, Whyte IM (September 2003). “The Hunter Serotonin Toxicity Criteria: simple and accurate diagnostic decision rules for serotonin toxicity” (PDF). QJM: Monthly Journal of the Association of Physicians 96 (9): 635–42. doi:10.1093/qjmed/hcg109. PMID 12925718.
Kolecki P (July–August 1997). “Isolated venlafaxine-induced serotonin syndrome”. Journal of Emergency Medicine 15 (4): 491–3. doi:10.1016/S0736-4679(97)00078-4. PMID 9279702.
Pan JJ, Shen WW (February 2003). “Serotonin syndrome induced by low-dose venlafaxine”. The Annals of Pharmacotherapy 37 (2): 209–11. doi:10.1345/aph.1C021. PMID 12549949.
Thundiyil JG, Kearney TE, Olson KR (March 2007). “Evolving epidemiology of drug-induced seizures reported to a Poison Control Center System” (PDF). Journal of Medical Toxicology 3 (1): 15–9. doi:10.1007/BF03161033. PMC 3550124. PMID 18072153.
Pacchiarotti I, Bond DJ, Baldessarini RJ, Nolen WA, Grunze H, Licht RW, Post RM, Berk M, Goodwin GM, Sachs GS, Tondo L, Findling RL, Youngstrom EA, Tohen M, Undurraga J, González-Pinto A, Goldberg JF, Yildiz A, Altshuler LL, Calabrese JR, Mitchell PB, Thase ME, Koukopoulos A, Colom F, Frye MA, Malhi GS, Fountoulakis KN, Vázquez G, Perlis RH, Ketter TA, Cassidy F, Akiskal H, Azorin JM, Valentí M, Mazzei DH, Lafer B, Kato T, Mazzarini L, Martínez-Aran A, Parker G, Souery D, Ozerdem A, McElroy SL, Girardi P, Bauer M, Yatham LN, Zarate CA, Nierenberg AA, Birmaher B, Kanba S, El-Mallakh RS, Serretti A, Rihmer Z, Young AH, Kotzalidis GD, MacQueen GM, Bowden CL, Ghaemi SN, Lopez-Jaramillo C, Rybakowski J, Ha K, Perugi G, Kasper S, Amsterdam JD, Hirschfeld RM, Kapczinski F, Vieta E (November 2013). “The International Society for Bipolar Disorders (ISBD) task force report on antidepressant use in bipolar disorders”. The American Journal of Psychiatry 170 (1): 1249–62. doi:10.1176/appi.ajp.2013.13020185. PMID 24030475.
Santos PM, López-García P, Navarro JS, Fernández AS, Sádaba B, Vidal JP (February 2007). “False positive phencyclidine results caused by venlafaxine” (PDF). The American Journal of Psychiatry 164 (2): 349. doi:10.1176/appi.ajp.164.2.349. PMID 17267806.
Sena SF, Kazimi S, Wu AH (April 2002). “False-positive phencyclidine immunoassay results caused by venlafaxine and O-desmethylvenlafaxine” (PDF). Clinical Chemistry 48 (4): 676–7. PMID 11901076.
Cipriani A, Furukawa TA, Salanti G, et al. (2009-02-28). “Comparative efficacy and acceptability of 12 new-generation antidepressants: a multiple-treatments meta-analysis.”. Lancet 373 (9665): 746-58. doi:10.1016/S0140-6736(09)60046-5. PMID 19185342.
Taylor D, Lenox-Smith A, Bradley A (June 2013). “A review of the suitability of duloxetine and venlafaxine for use in patients with depression in primary care with a focus on cardiovascular safety, suicide and mortality due to antidepressant overdose.”. Therapeutic Advances in Psychopharmacology 3 (3): 151–61. doi:10.1177/2045125312472890. PMC 3805457. PMID 24167687.
Hanekamp BB, Zijlstra JG, Tulleken JE, Ligtenberg JJ, van der Werf TS, Hofstra LS (2005). “Serotonin syndrome and rhabdomyolysis in venlafaxine poisoning: a case report” (PDF). The Netherlands Journal of Medicine 63 (8): 316–8. PMID 16186642.
Goeringer KE, McIntyre IM, Drummer OH (2001). “Postmortem tissue concentrations of venlafaxine”. Forensic Science International 121 (1–2): 70–5. doi:10.1016/S0379-0738(01)00455-8. PMID 11516890.
Wellington K, Perry CM (2001). “Venlafaxine extended-release: a review of its use in the management of major depression” (PDF). CNS Drugs 15 (8): 643–69. doi:10.2165/00023210-200115080-00007. PMID 11524036.
Delgado PL, Moreno FA (2000). “Role of norepinephrine in depression”. Journal of Clinical Psychiatry 61 (Suppl. 1): 5–12. PMID 10703757.
Schreiber S, Bleich A, Pick CG (February–April 2002). “Venlafaxine and mirtazapine: different mechanisms of antidepressant action, common opioid-mediated antinociceptive effects—a possible opioid involvement in severe depression?”. Journal of Molecular Neuroscience, MN 18 (1–2): 143–9. doi:10.1385/JMN:18:1-2:143. PMID 11931344.
Sabatucci JP, Mahaney PE, Leiter J, Johnston G, Burroughs K, Cosmi S, Zhang Y, Ho D, Deecher DC, Trybulski E. (2010) Heterocyclic cycloalkanol ethylamines as norepinephrine reuptake inhibitors. Bioorg. Med. Chem. Lett., 20 (9): 2809-12. PMID 20378347
Shams ME, Arneth B, Hiemke C, Dragicevic A, Müller MJ, Kaiser R, Lackner K, Härtter S; Arneth; Hiemke; Dragicevic; Müller; Kaiser; Lackner; Härtter (October 2006). “CYP2D6 polymorphism and clinical effect of the antidepressant venlafaxine”. Journal of Clinical Pharmacy and Therapeutics 31 (5): 493–502. doi:10.1111/j.1365-2710.2006.00763.x. PMID 16958828.
Uhr M, Tontsch A, Namendorf C, Ripke S, Lucae S, Ising M, Dose T, Ebinger M, Rosenhagen M, Kohli M, Kloiber S, Salyakina D, Bettecken T, Specht M, Pütz B, Binder EB, Müller-Myhsok B, Holsboer F; Tontsch; Namendorf; Ripke; Lucae; Ising; Dose; Ebinger et al. (2008). “Polymorphisms in the drug transporter gene ABCB1 predict antidepressant treatment response in depression”. Neuron 57 (2): 203–209. doi:10.1016/j.neuron.2007.11.017. PMID 18215618.
Whyte IM, Dawson AH, Buckley NA; Dawson; Buckley (May 2003). “Relative toxicity of venlafaxine and selective serotonin reuptake inhibitors in overdose compared to tricyclic antidepressants” (PDF). QJM: Monthly Journal of the Association of Physicians 96 (5): 369–74. doi:10.1093/qjmed/hcg062. PMID 12702786.

pmc.ncbi.nlm.nih.gov

White N, Litovitz T, Clancy C (December 2008). “Suicidal antidepressant overdoses: a comparative analysis by antidepressant type.”. Journal of Medical Toxicology 4 (4): 238–50. doi:10.1007/BF03161207. PMC 3550116. PMID 19031375.
Nakhai-Pour HR, Broy P, Bérard A (2010). “Use of antidepressants during pregnancy and the risk of spontaneous abortion”. Canadian Medical Association Journal 182 (10): 1031–1037. doi:10.1503/cmaj.091208. PMC 2900326. PMID 20513781. 非専門家向けの内容要旨.
Gibbons RD, Brown CH, Hur K, Davis J, Mann JJ (June 2012). “Suicidal thoughts and behavior with antidepressant treatment: reanalysis of the randomized placebo-controlled studies of fluoxetine and venlafaxine”. Arch. Gen. Psychiatry 69 (6): 580–7. doi:10.1001/archgenpsychiatry.2011.2048. PMC 3367101. PMID 22309973.
Rubino A, Roskell N, Tennis P, Mines D, Weich S, Andrews E (2007). “Risk of suicide during treatment with venlafaxine, citalopram, fluoxetine, and dothiepin: retrospective cohort study” (PDF). British Medical Journal 334 (7587): 242. doi:10.1136/bmj.39041.445104.BE. PMC 1790752. PMID 17164297.
Brent DA, Emslie GJ, Clarke GN, Asarnow J, Spirito A, Ritz L, Vitiello B, Iyengar S, Birmaher B, Ryan ND, Zelazny J, Onorato M, Kennard B, Mayes TL, Debar LL, McCracken JT, Strober M, Suddath R, Leonard H, Porta G, Keller MB (April 2009). “Predictors of spontaneous and systematically assessed suicidal adverse events in the treatment of SSRI-resistant depression in adolescents (TORDIA) study” (PDF). The American Journal of Psychiatry 166 (4): 418–26. doi:10.1176/appi.ajp.2008.08070976. PMC 3593721. PMID 19223438.
Campagne DM (2005). “Venlafaxine and Serious Withdrawal Symptoms: Warning to Drivers”. Medscape General Medicine (Ncbi.nlm.nih.gov) 7 (3): 22. PMC 1681629. PMID 16369248.
Thundiyil JG, Kearney TE, Olson KR (March 2007). “Evolving epidemiology of drug-induced seizures reported to a Poison Control Center System” (PDF). Journal of Medical Toxicology 3 (1): 15–9. doi:10.1007/BF03161033. PMC 3550124. PMID 18072153.
Taylor D, Lenox-Smith A, Bradley A (June 2013). “A review of the suitability of duloxetine and venlafaxine for use in patients with depression in primary care with a focus on cardiovascular safety, suicide and mortality due to antidepressant overdose.”. Therapeutic Advances in Psychopharmacology 3 (3): 151–61. doi:10.1177/2045125312472890. PMC 3805457. PMID 24167687.

ncbi.nlm.nih.gov

White N, Litovitz T, Clancy C (December 2008). “Suicidal antidepressant overdoses: a comparative analysis by antidepressant type.”. Journal of Medical Toxicology 4 (4): 238–50. doi:10.1007/BF03161207. PMC 3550116. PMID 19031375.
Nakhai-Pour HR, Broy P, Bérard A (2010). “Use of antidepressants during pregnancy and the risk of spontaneous abortion”. Canadian Medical Association Journal 182 (10): 1031–1037. doi:10.1503/cmaj.091208. PMC 2900326. PMID 20513781. 非専門家向けの内容要旨.
Gibbons RD, Brown CH, Hur K, Davis J, Mann JJ (June 2012). “Suicidal thoughts and behavior with antidepressant treatment: reanalysis of the randomized placebo-controlled studies of fluoxetine and venlafaxine”. Arch. Gen. Psychiatry 69 (6): 580–7. doi:10.1001/archgenpsychiatry.2011.2048. PMC 3367101. PMID 22309973.
Campagne DM (2005). “Venlafaxine and Serious Withdrawal Symptoms: Warning to Drivers”. Medscape General Medicine (Ncbi.nlm.nih.gov) 7 (3): 22. PMC 1681629. PMID 16369248.
Taylor D, Lenox-Smith A, Bradley A (June 2013). “A review of the suitability of duloxetine and venlafaxine for use in patients with depression in primary care with a focus on cardiovascular safety, suicide and mortality due to antidepressant overdose.”. Therapeutic Advances in Psychopharmacology 3 (3): 151–61. doi:10.1177/2045125312472890. PMC 3805457. PMID 24167687.

dailymed.nlm.nih.gov

“VENLAFAXINE (venlafaxine hydrochloride) tablet [Aurobindo Pharma Limited]”. DailyMed. Aurobindo Pharma Limited (2013年2月). 2013年11月6日閲覧。

njmonline.nl

Hanekamp BB, Zijlstra JG, Tulleken JE, Ligtenberg JJ, van der Werf TS, Hofstra LS (2005). “Serotonin syndrome and rhabdomyolysis in venlafaxine poisoning: a case report” (PDF). The Netherlands Journal of Medicine 63 (8): 316–8. PMID 16186642.

oxfordjournals.org

qjmed.oxfordjournals.org

Dunkley EJ, Isbister GK, Sibbritt D, Dawson AH, Whyte IM (September 2003). “The Hunter Serotonin Toxicity Criteria: simple and accurate diagnostic decision rules for serotonin toxicity” (PDF). QJM: Monthly Journal of the Association of Physicians 96 (9): 635–42. doi:10.1093/qjmed/hcg109. PMID 12925718.
Whyte IM, Dawson AH, Buckley NA; Dawson; Buckley (May 2003). “Relative toxicity of venlafaxine and selective serotonin reuptake inhibitors in overdose compared to tricyclic antidepressants” (PDF). QJM: Monthly Journal of the Association of Physicians 96 (5): 369–74. doi:10.1093/qjmed/hcg062. PMID 12702786.

pmda.go.jp

info.pmda.go.jp

“イフェクサーSRカプセル37.5mg／イフェクサーSRカプセル75mg 添付文書” (2015年9月). 2016年11月6日閲覧。

priory.com

“Hallucinations as a side effect of venlafaxine treatment”. Psychiatry On-line. 2008年6月17日閲覧。

psychiatryonline.org

ajp.psychiatryonline.org

Brent DA, Emslie GJ, Clarke GN, Asarnow J, Spirito A, Ritz L, Vitiello B, Iyengar S, Birmaher B, Ryan ND, Zelazny J, Onorato M, Kennard B, Mayes TL, Debar LL, McCracken JT, Strober M, Suddath R, Leonard H, Porta G, Keller MB (April 2009). “Predictors of spontaneous and systematically assessed suicidal adverse events in the treatment of SSRI-resistant depression in adolescents (TORDIA) study” (PDF). The American Journal of Psychiatry 166 (4): 418–26. doi:10.1176/appi.ajp.2008.08070976. PMC 3593721. PMID 19223438.
Pacchiarotti I, Bond DJ, Baldessarini RJ, Nolen WA, Grunze H, Licht RW, Post RM, Berk M, Goodwin GM, Sachs GS, Tondo L, Findling RL, Youngstrom EA, Tohen M, Undurraga J, González-Pinto A, Goldberg JF, Yildiz A, Altshuler LL, Calabrese JR, Mitchell PB, Thase ME, Koukopoulos A, Colom F, Frye MA, Malhi GS, Fountoulakis KN, Vázquez G, Perlis RH, Ketter TA, Cassidy F, Akiskal H, Azorin JM, Valentí M, Mazzei DH, Lafer B, Kato T, Mazzarini L, Martínez-Aran A, Parker G, Souery D, Ozerdem A, McElroy SL, Girardi P, Bauer M, Yatham LN, Zarate CA, Nierenberg AA, Birmaher B, Kanba S, El-Mallakh RS, Serretti A, Rihmer Z, Young AH, Kotzalidis GD, MacQueen GM, Bowden CL, Ghaemi SN, Lopez-Jaramillo C, Rybakowski J, Ha K, Perugi G, Kasper S, Amsterdam JD, Hirschfeld RM, Kapczinski F, Vieta E (November 2013). “The International Society for Bipolar Disorders (ISBD) task force report on antidepressant use in bipolar disorders”. The American Journal of Psychiatry 170 (1): 1249–62. doi:10.1176/appi.ajp.2013.13020185. PMID 24030475.
Santos PM, López-García P, Navarro JS, Fernández AS, Sádaba B, Vidal JP (February 2007). “False positive phencyclidine results caused by venlafaxine” (PDF). The American Journal of Psychiatry 164 (2): 349. doi:10.1176/appi.ajp.164.2.349. PMID 17267806.

secretariat.ne.jp

日本うつ病学会、気分障害のガイドライン作成委員会『日本うつ病学会治療ガイドライン (pdf)』（レポート）（2012 Ver.1版）、2012年7月26日、34–35頁。
日本うつ病学会、気分障害のガイドライン作成委員会『日本うつ病学会治療ガイドライン (pdf)』（レポート）（2012 Ver.1版）、2012年7月26日、28頁。

snpedia.com

“Rs2032583 -SNPedia”. Snpedia.com. 2013年11月21日閲覧。^{[信頼性要検証]}

springer.com

link.springer.com

stanford.edu

med.stanford.edu

“Medications”. Stanford University School of Medicine, Center for Narcolepsy (2003年2月7日). 2007年9月3日閲覧。

tga.gov.au

ebs.tga.gov.au

“APO-VENLAFAXINE XR CAPSULES” (PDF). TGA eBusiness Services. Apotex Pty Ltd (2012年4月13日). 2013年11月6日閲覧。

thelancet.com

Cipriani A, Furukawa TA, Salanti G, et al. (2009-02-28). “Comparative efficacy and acceptability of 12 new-generation antidepressants: a multiple-treatments meta-analysis.”. Lancet 373 (9665): 746-58. doi:10.1016/S0140-6736(09)60046-5. PMID 19185342.

web.archive.org

“Effexor Medicines Data Sheet”. Wyeth Pharmaceuticals Inc (2006年). 2006年9月17日時点のオリジナルよりアーカイブ。2006年9月17日閲覧。
“Overview for December 13 Meeting of Psychopharmacologic Drugs Advisory Committee” (PDF). Food and Drug Administration: Center for Drug Evaluation and Research (2006年11月16日). 2007年3月16日時点のオリジナルよりアーカイブ。2007年6月20日閲覧。

wyeth.com

“Effexor Medicines Data Sheet”. Wyeth Pharmaceuticals Inc (2006年). 2006年9月17日時点のオリジナルよりアーカイブ。2006年9月17日閲覧。